Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 3:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: C. Diff Clear all
Completed No phase listed Observational Accepts healthy volunteers

Pathogenic Mechanisms in C Diff Infection and Colitis

NCT01930032
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Jun 27, 2026, 3:06 AM EDT
Recruiting No phase listed Observational

C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.

NCT07250724
View directory record Official record
Conditions
Clostridioides Difficile Infection Recurrence
Interventions
Participants that are undergoing standard of care antibiotic treatment for their second C. Diff infection will be followed for 8 weeks after completing antibiotic treatment.
Other
Lead sponsor
Bactolife A/S
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
Atlanta, Georgia • Royal Oak, Michigan • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jun 27, 2026, 3:06 AM EDT
Terminated Phase 2 Interventional Results available

FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI

NCT02255305
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
FMT, Antimicrobials
Biological · Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Jun 27, 2026, 3:06 AM EDT
Terminated Phase 3 Interventional Results available

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4)

NCT05153499
View directory record Official record
Conditions
Recurrent C. Difficile Infection
Interventions
CP101, Placebo
Biological · Other
Lead sponsor
Finch Research and Development LLC.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
61
States / cities
Phoenix, Arizona • Mission Hills, California • Oakland, California + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Jun 27, 2026, 3:06 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis

NCT01973465
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Stool
Biological
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Jun 27, 2026, 3:06 AM EDT
Recruiting Phase 3 Interventional

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT06237452
View directory record Official record
Conditions
Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious
Interventions
VE303, Placebo
Biological
Lead sponsor
Vedanta Biosciences, Inc.
Industry
Eligibility
12 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
84
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jun 27, 2026, 3:06 AM EDT
Completed No phase listed Observational

Association Between Response to Treatment of C. Diff Colitis and Anti-C.Diff Toxin Antibody

NCT00304408
View directory record Official record
Conditions
Clostridium Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
Interventions
Not listed
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2010 · Synced Jun 27, 2026, 3:06 AM EDT
Terminated Not applicable Interventional Results available

Intracolonic Vancomycin Therapy in Severe C. Diff Colitis

NCT01346059
View directory record Official record
Conditions
Colitis
Interventions
Vancomycin, Saline
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Jun 27, 2026, 3:06 AM EDT
Completed Phase 3 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)

NCT03931941
View directory record Official record
Conditions
Clostridium Difficile Infection, Infection, Communicable Diseases
Interventions
RBX2660
Drug
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
46
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • Oxnard, California + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Jun 27, 2026, 3:06 AM EDT
Completed Phase 2 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

NCT02299570
View directory record Official record
Conditions
Enterocolitis Clostridium Difficile Recurrent
Interventions
RBX2660 (microbiota suspension), Placebo
Biological · Other
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
19
States / cities
Phoenix, Arizona • Aurora, Colorado • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Jun 27, 2026, 3:06 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT03788434
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection, Clostridium Difficile, Clostridioides Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile, CDI
Interventions
VE303, Placebo
Drug
Lead sponsor
Vedanta Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
29
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Canoga Park, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Jun 27, 2026, 3:06 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Probiotics for Prevention of Antibiotic Associated Diarrhea and Clostridium Difficile Associated Disease

NCT02076438
View directory record Official record
Conditions
Diarrhea
Interventions
Probiotics
Dietary Supplement
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 89 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Jun 27, 2026, 3:06 AM EDT
Completed No phase listed Observational

Observational Study of C. Diff in Post-Transplant Patients

NCT02747017
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Minneapolis, Minnesota • Rochester, Minnesota • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Jun 27, 2026, 3:06 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)

NCT00269399
View directory record Official record
Conditions
Clostridium Infections, Diarrhea
Interventions
Rifaximin (Xifaxan), Vancomycin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
63
States / cities
Scottsdale, Arizona • Redlands, California • Longmont, Colorado + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2019 · Synced Jun 27, 2026, 3:06 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

NCT03497806
View directory record Official record
Conditions
Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection, C. Diff, CDI, Recurrent C. Diff, rCDI, C. Difficile, Recurrent CDI, FMT, Fecal Microbiota, Fecal Transplant
Interventions
CP101
Biological
Lead sponsor
Finch Research and Development LLC.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
53
States / cities
Scottsdale, Arizona • Los Angeles, California • Murrieta, California + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Jun 27, 2026, 3:06 AM EDT
Terminated Phase 4 Interventional Results available

Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).

NCT04626947
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease, C. Diff. Infections
Interventions
Bezlotoxumab
Biological
Lead sponsor
David Binion, MD
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jun 27, 2026, 3:06 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults

NCT05805826
View directory record Official record
Conditions
Clostridoides Difficile Associated Disease
Interventions
C. difficile vaccine (previously studied formulation)., C. difficile vaccine formulation 1., C. difficile vaccine formulation 2., C. difficile vaccine formulation 3., Saline Placebo.
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
936 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2031
U.S. locations
23
States / cities
Phoenix, Arizona • Anaheim, California • Doral, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jun 27, 2026, 3:06 AM EDT
Completed No phase listed Observational

Fecal Microbiota Transplantation (FMT) in Clostridium Difficile Infection (CDI) Not Responding to Antibiotics

NCT03117582
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Stool specimen
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 99 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Jun 27, 2026, 3:06 AM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection

NCT05831189
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
RBX2660
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
North Little Rock, Arkansas • Camarillo, California • Hamden, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jun 27, 2026, 3:06 AM EDT
Terminated Phase 4 Interventional Results available

IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff

NCT00177970
View directory record Official record
Conditions
Clostridium Difficile-associated Diarrhea (CDAD)
Interventions
intravenous immunoglobulin G (IVIG), Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
4
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Jun 27, 2026, 3:06 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection

NCT03595553
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
Ridinilazole, Vancomycin
Drug
Lead sponsor
Summit Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
49
States / cities
Birmingham, Alabama • Sun City, Arizona • Los Angeles, California + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Jun 27, 2026, 3:06 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin

NCT07221708
View directory record Official record
Conditions
Clostridioides Difficile, Vancomycin Resistance Enterococcus Faecium
Interventions
Vancomycin (POC)
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
65 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Glen Burnie, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jun 27, 2026, 3:06 AM EDT
Not listed Phase 1 Interventional

Fecal Transplant for Pediatric Patients Who Have Recurrent C-diff Infection

NCT02134392
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Fecal Microbiota Transplantation
Biological
Lead sponsor
Jonathan Gisser
Other
Eligibility
2 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Jun 27, 2026, 3:06 AM EDT
Completed Phase 2 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

NCT02589847
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
RBX2660, Standard of Care Antibiotics
Biological · Drug
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
28
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • Sacramento, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Jun 27, 2026, 3:06 AM EDT